Investigator studied current treatment patterns and attrition rates in metastatic clear cell renal cell carcinoma using a large, US nationwide cohort.

Prior to 12 months, all TKI changes were made due to grade ≥ ... choice taking into consideration the long-term safety profile.” 1. Russell-Smith TA, Verma S, Liu Y, Sikirica S, Janjan N.

Limertinib is the 14th product in Innovent's commercial portfolio and represents a cutting-edge addition to its strong TKI franchise ... robust efficacy and safety profile. Independent review ...

Safety and efficacy of sintilimab in combination with SBRT and LDRT in PD-L1 positive treatment naïve-stage IV non-small cell lung cancer: A phase I study (IHC study). This is an ASCO Meeting Abstract ...

“However, many patients still receive TKI or ICI monotherapy in this setting.” The investigators had no information on patients’ clinical profile or socioeconomic status, limiting analyses ...